XML 36 R20.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2021
Share-based Payment Arrangement [Abstract] |
STOCK-BASED COMPENSATION |
| 13. | STOCK-BASED COMPENSATION.
The Company has two equity incentive compensation plans: a 2006 Stock Incentive Plan and a 2016 Stock Incentive Plan. 2006 Stock Incentive Plan – The 2006 Stock Incentive Plan authorized the issuance of incentive stock options (“ISOs”) and non-qualified stock options (“NQOs”), restricted stock, restricted stock units, stock appreciation rights, direct stock issuances and other stock-based awards to the Company’s officers, directors or key employees or to consultants that do business with the Company for up to an aggregate of 1,715,000 shares of common stock. In June 2016, the 2006 Stock Incentive plan was terminated, except to the extent of issued and outstanding unvested stock awards and options. 2016 Stock Incentive Plan – On June 16, 2016, the Company’s shareholders approved the 2016 Stock Incentive Plan, which authorizes the issuance of ISOs, NQOs, restricted stock, restricted stock units, stock appreciation rights, direct stock issuances and other stock-based awards to the Company’s officers, directors or key employees or to consultants that do business with the Company initially for up to an aggregate of 1,150,000 shares of common stock. On June 14, 2018, the Company’s shareholders approved an increase to the aggregate number of shares authorized under the 2016 Stock Incentive Plan to 3,650,000 shares. On November 7, 2019, the Company’s shareholders approved an increase to the aggregate number of shares authorized under the 2016 Stock Incentive Plan to 5,650,000 shares. On November 18, 2020, the Company’s shareholders approved an increase to the aggregate number of shares authorized under the 2016 Stock Incentive Plan to 7,400,000 shares. Stock Options – Summaries of the status of Company’s stock option plans as of December 31, 2021 and 2020 and of changes in options outstanding under the Company’s plans during those years are as follows (number of shares in thousands):
|  | Years Ended December 31, |
|  | 2021 |  |  | 2020 |
|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Number of Shares |  |  | Weighted Average Exercise Price |
Outstanding at beginning of year |  |  | 207 |  |  | $ | 4.16 |  |  |  | 229 |  |  | $ | 4.15 |
Options exercised |  |  | (124 | ) |  |  | 3.74 |  |  |  | (22 | ) |  |  | 3.74 |
Options expired |  |  | (9 | ) |  |  | 12.90 |  |  |  | — |  |  |  | — |
Outstanding at end of year |  |  | 74 |  |  | $ | 3.74 |  |  |  | 207 |  |  | $ | 4.16 |
Options exercisable at end of year |  |  | 74 |  |  | $ | 3.74 |  |  |  | 207 |  |  | $ | 4.16 |
Stock options outstanding as of December 31, 2021 were as follows (number of shares in thousands):
|  |  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Prices |  |  | Number Outstanding |  |  | Weighted- Average Remaining Contractual Life (yrs.) |  |  | Weighted- Average Exercise Price |  |  | Number Exercisable |  |  | Weighted- Average Exercise Price |
$ | 3.74 |  |  |  | 74 |  |  |  | 1.46 |  |  | $ | 3.74 |  |  |  | 74 |  |  | $ | 3.74 |
The aggregate intrinsic value of the options outstanding was $79,000, $262,000 and $0 as of December 31, 2021, 2020 and 2019, respectively. Restricted Stock – A summary of unvested restricted stock activity is as follows (shares in thousands):
|  | Number of Shares |  |  | Weighted- Average Grant Date Fair Value Per Share |
Unvested at December 31, 2019 |  |  | 2,201 |  |  | $ | 1.84 |
Issued |  |  | 1,663 |  |  | $ | 1.25 |
Vested |  |  | (1,290 | ) |  | $ | 2.08 |
Canceled |  |  | (314 | ) |  | $ | 1.33 |
Unvested at December 31, 2020 |  |  | 2,260 |  |  | $ | 1.34 |
Issued |  |  | 750 |  |  | $ | 5.76 |
Vested |  |  | (1,525 | ) |  | $ | 1.64 |
Canceled |  |  | (98 | ) |  | $ | 2.77 |
Unvested at December 31, 2021 |  |  | 1,387 |  |  | $ | 3.30 |
The fair value of the common stock at vesting aggregated $8,810,000, $1,639,000 and $599,000 for the years ended December 31, 2021, 2020 and 2019, respectively. Stock-based compensation expense related to employee and non-employee restricted stock and option grants recognized in the accompanying consolidated statements of operations, was as follows (in thousands):
|  | Years Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Employees |  | $ | 1,758 |  |  | $ | 2,025 |  |  | $ | 2,422 |
Non-employees |  |  | 1,125 |  |  |  | 654 |  |  |  | 387 |
Total stock-based compensation expense |  | $ | 2,883 |  |  | $ | 2,679 |  |  | $ | 2,809 |
Employee grants typically have a two or three-year vesting schedule, while non-employee grants have a one-year vesting schedule. At December 31, 2021, the total compensation expense related to unvested awards which had not been recognized was $3,036,000 and the associated weighted-average period over which the compensation expense attributable to those unvested awards will be recognized was approximately 0.61 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration